In short
Mbs2320 is being studied in clinical trials for people with idiopathic pulmonary fibrosis (IPF), a long-term lung disease that causes scarring. The trial data focus on whether Mbs2320 can improve or slow loss of lung function, and they also look at safety and treatment effects in adults with IPF.
Key points
- Mbs2320 is being studied in a clinical trial for idiopathic pulmonary fibrosis, also called IPF. The available trial was a Phase 2 interventional study and it has been completed. It compared daily oral Mbs2320 with placebo over 12 weeks. The main goal was to measure change in forced vital capacity, which is a test of lung function. The study enrolled 306 people with IPF.
Trial overview
The available clinical trial studied Mbs2320 in people with idiopathic pulmonary fibrosis (IPF), a disease that causes scarring in the lungs and can make breathing harder.
This was an interventional study, which means researchers gave a study treatment and compared results between groups.
Who was studied
The study focused on participants with IPF.
The source data do not list extra entry rules such as age range, disease stage, or other medical requirements, so those details are not available here.
A total of 306 participants were enrolled.
Treatment and comparison
Participants received daily oral Mbs2320 or placebo, which is a look-alike treatment with no active study drug.
The trial compared Mbs2320 capsules 40 mg with placebo capsules that matched the study drug.
The brief study summary says the treatment period lasted 12 weeks.
What the trial measured
The main outcome was the change from baseline in forced vital capacity (FVC) compared with placebo up to Week 12 or until treatment was stopped.
FVC is the amount of air a person can blow out after taking the deepest breath possible, so it is an important measure of lung function.
The study summary also says the trial aimed to evaluate the effect of daily oral dosing of Mbs2320 on the absolute change in FVC measured in milliliters.
Trial design and phase
The study was a Phase 2 trial.
Phase 2 studies are usually done after early safety testing and are designed to learn more about whether a treatment may help the condition being studied.
The trial status is listed as Completed.
What the results section means for patients
From the source data, the main question in this trial was whether Mbs2320 could change lung function in people with IPF compared with placebo.
The trial does not provide result numbers in the source material, so this article only summarizes the study design, target group, and outcome being measured.
Because the trial was completed, the study question has been tested in a real patient group, but the provided data do not include the final findings.